medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2011, Number 05

<< Back Next >>

Ginecol Obstet Mex 2011; 79 (05)

Role of uric acid in preeclampsia-eclampsia

Vázquez-Rodríguez JG, Rico-Trejo EI

Language: Spanish
References: 37
Page: 292-297
PDF size: 303.24 Kb.


ABSTRACT

Uric acid is a terminal metabolite of the degradation of nucleotides, which increases their blood levels in patients with preeclampsiaeclampsia, increasing its synthesis by damage and death of trophoblastic cells in proliferation and decreased urinary excretion due a lower glomerular filtration rate and increased absorption in the proximal tubule. Hyperuricemia (› 4.5 mg/dL) is the first biomarker of the clinical chemistry considered as an early evidence of disease (≤ 20 weeks gestation). Uric acid concentrations are not only a criterion for establishing the correct diagnosis and the differential with other hypertensive states, but an indication of termination of pregnancy, often by cesarean section. Hyperuricemia has also demonstrated its usefulness as a predictor of maternal and fetal complications and maternal sequelae of late postpartum. Several studies have demonstrated its influence on the genesis of preeclampsia-eclampsia, either alone or jointly with other known processes (metabolic syndro me, oxidative stress, inflammation cascade, angiogenesis) that have a proven role in perpetuating the endothelial damage and maternal vascular smooth muscle cells. Further research is needed in large-scale clinical and experimental studies that expand our knowledge about the usefulness of uric acid as a biomarker of preeclampsia-eclampsia to allow early prevention and reducing the prevalence.


REFERENCES

  1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183(Supp I):S1-S22.

  2. Díaz-Chavarría DF. Mortalidad materna, una tarea inconclusa. México. Fundar, Centro de Análisis e Investigación, 2006. También disponible electrónicamente en: www.fundar.org.mx

  3. Búsqueda intencionada de muertes maternas en México. Informe 2008. México. Dirección General de Información en Salud. Secretaría de Salud. 2010. También disponible electrónicamente en: http://www.cemese.salud.gob.mx/mdex.html, en http://www.dgis.salud.gob.mx y en http://www.sinais.salud. gob.mx

  4. Bourjeily G, Millar M. Obstetric disorders in the UCI. Clin Chest Med 2009;30:89-102.

  5. American College of Obstetricians and Gynecologists (ACOG). Diagnosis and management of preeclampsia and eclampsia. Practice bulletin No. 33. Obstet Gynecol 2002;99:159-167.

  6. Pridjian G, Puschett JB. Preeclampsia. Part 1: Clinical and pathophysiologic considerations. Obstet Gynecol Surv 2002;57:598-618.

  7. Briones GJC. Preeclampsia-eclampsia. México: Distribuidora y Editora Mexicana, 2000.

  8. Vázquez RJG. Hipertensión arterial por preeclampsia-eclampsia. México: Prado, 2007.

  9. Voet D, Voet JG, Pratt CW. Degradación de nucleótidos. Fundamentos de Bioquímica, 2a ed. Buenos Aires: Médica Panamericana, 2007.

  10. Rajasingam D, Seed PT, Briley AL. A prospective study of pregnancy outcome and biomarkers of oxidative stress in nulliparous obese women. Am J Obstet Gynecol 2009;200:395-399.

  11. Chesnutt AN. Physiology of normal pregnancy. Crit Care Clin 2004;20:609-615.

  12. Boyle JA, Campbell S, Duncan AM, Greig WR, Buchanan WW. Serum uric acid levels in normal pregnancy with observations on the renal excretion of urate in pregnancy, J Clin Pathol 1966;19:501-503.

  13. Norma y Procedimientos de Ginecología y Obstetricia. México. Instituto Nacional de Perinatología (INPER), 2002.

  14. Norma Técnico Medico para la Prevención y Manejo de la Preeclampsia-Eclampsia. México. Dirección General de Prestaciones Médicas. Instituto Mexicano del Seguro Social (IMSS), 2005.

  15. Guías de Practica Clínica. Detección y Diagnostico de Enfermedades Hipertensivas del Embarazo. México. Dirección General de Prestaciones Médicas. Instituto Mexicano del Seguro Social (IMSS), 2009.

  16. Koopmans CM, Van Pampus MG, Groen H, Aarnoudse JG, et al. Accuracy of serum uric acid as a predictive test for maternal complications in pre-eclampsia: bivariate meta-analysis and decision analysis. Eur Jour Obstet Gyn Reprod Biol 2009;146:8-14.

  17. Powers RW, Bodnar LM, Ness RB, Cooper KM, et al. Uric acid concentrations in early pregnancy among preeclamptic women with gestational hyperuricemia at delivery. Am J Obstet Gynecol 2006;194: 160-168.

  18. Ndayambagye EBC, Nakalembe M, Kaye DK. Factors associated with persistent hypertension after puerperium among women with preeclampsia-eclampsia in Mulago Hospital, Uganda. BMC Pregnancy and Childbirth 2010;5:10-12.

  19. Thangaratinam S, Ismail KMK, Sharp S, Coomarasamy A, Khan KS. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG 2006;113:369-378.

  20. Gupta A, Kaliaperumal S, Setia S, Suchi ST, Rao VA. Retinopathy in preeclampsia: association with birth weight and uric acid level. Retina 2008;28:1104-1110.

  21. Bainbridge SA, Roberts JM. Uric acid as a pathogenic factor in preeclampsia. Placenta 2008;29 (SuppI):S67-S72.

  22. Gown V, Al-Zakwani I. Prevalence of cesarean delivery in preeclamptic patients with elevated uric acid. Hypertension in pregnancy 2010;29:231-235.

  23. Chamy PV, Madrid AE, Aránguiz GN, Guerra HV, y col. Perfil clínico de embarazadas con preeclampsia y embarazo no complicado. Rev Chil Obstet Ginecol 2004;69:361-367.

  24. Laughon SK, Catov J, Roberts JM. Uric acid concentrations are associated with insulin resistance and birthweight in normotensive pregnant women. Am J Obstet Gynecol 2009;201(582):1-6.

  25. Kang DH, Finch J, Nakagawa T, Karumanchi SA, et al. Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. J Hypert 2004;22:229-235.

  26. Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol 2000;49:511-516.

  27. Kanabrocki EL, Third JL, Ryan MD, Nemchausky BA, et al. Circadian relationship of serum uric acid and nitric oxide. JAMA 2000;283:2240-2241.

  28. Butler R, Morris AD, Belch JJF, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000;35:746-751.

  29. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure. Circulation 2002;105:2619-2624.

  30. Finch JL, Mu W, Parra G, Feig DL, et al. Hyperuricemia induces endothelial dysfunction in rats (abstracts). J Am Soc Nephrol 2003;14:143A.

  31. Kang DH, Yoo ES, Kim MY, Park JE, et al. Uric acid induces C-reactive protein expression via upregulation of angiotensin type I receptor in vascular endothelial and smooth muscle cells (abstract). J Am Soc Nephrol 2003;14:136A.

  32. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et. al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888-2897.

  33. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, et al. Uric acid stimulates MCP-1 production in vascular smooth muscle cells via MAPK and COX-2. Hypertension. 2003;41:1287-93.

  34. Lam Ch, Lim KH, Kang DH, Karumanchi SA. Uric acid and preeclampsia. Semin Nephrol 2005;25:56-60.




2020     |     www.medigraphic.com